Shots:
- Algen has entered into a multi-target collaboration with AstraZeneca to accelerate novel immunology target discovery, leveraging the AlgenBrain platform
- As per the deal, AstraZeneca will receive exclusive rights to develop and commercialize therapies for selected targets identified through the partnership in exchange for ~555M incl. upfront, development, regulatory & commercial milestone payments
- AlgenBrain models disease progression by mapping billions of RNA changes to functional outcomes & therapeutic index via high-throughput gene modulation, allowing the discovery of genes that, when targeted, could reverse disease processes
Ref: BusinessWire | Image: AstraZeneca and Algen Biotechnologies | Press Release
Related News:- Hinge Bio Collaborates with Kyorin Pharmaceutical to Advance HB2198 in Japan for Autoimmune Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
